New Malaria Vaccine first to achieve over 75% efficacy
Researchers at Oxford’s Jenner Institute announced that the early stages of their Malaria vaccine trials have demonstrated over 77% efficacy, making it the first vaccine to reach the WHO’s target of 75% efficacy.
Malaria is one of the leading causes of death in children, with more than 400,000 people killed each year, particularly children located in Sub-Saharan Africa.
The researchers have reported results from their Phase IIb clinical trial involving 450 children over a follow up period of 12 months. The children were enrolled in Burkina Faso, which is in the top ten countries most affected by malaria. A follow up trial is now underway, involving 4,800 children aged 5-36 months spread across four countries.
The children received three doses, each given a month apart from May 2019 to August 2019 -- the Summer months being a peak seasonal malaria transmission period. The clinical trial reported that the doses were well-tolerated with no recorded severe reactions.
Over time, antibody levels did decline, but were reportedly restored to the peak levels following primary vaccination when a fourth dose was given after 12 months.
Given the severity of the impacts malaria has on child mortality, and the overall expense of other preventative measures such as bed nets, insecticides, and antimalarial drugs, a vaccine with such a high efficacy rate could potentially be a game-changer.
It is planned that the vaccine will be manufactured on a much larger scale at a low cost by SII, which is also involved in the Oxford/Astra-Zeneca vaccine production.
Want to learn more?
In addition to reporting clinical trial news and stories from within the patient community, we operate Citrus, a fully integrated recruitment and retention software. Citrus fits any clinical trial and simplifies the implementation of patient engagement in your clinical trial. Whether you are already working with CTMS systems or not, Citrus is the perfect add-on to make patient interaction effective.
Since 2015, our team has been hard at work raising awareness of clinical trials across the globe. A Forbes ‘30 Under 30’ company and a graduate of the renowned Techstar program in New York, Citruslabs is at the forefront of patient recruitment and retention technologies. With over 3 million patients now recorded on our databases, our patient recruitment dashboard is fast becoming the most efficient method of trial recruitment.
Now a #1 health app in 17 countries, our Mindmate app is helping to revolutionize the way we think about healthcare. Mindmate “[takes] senior care into the digital age” (Forbes, 2018) by providing people with the cognitive decline the essential tools to help them rebuild and maintain strong mental health. Trusted by millions of users, our health community continues to grow as the content available expands to the needs of individuals today.
With more than 200 research sites now using the Citrus platform to screen thousands of patients every month, researchers are now well on their way to finding new treatments for hundreds of different health conditions - something that just would not be possible without a technological solution. Make sure that your clinical trial is in the lucky 12% and turn that luck into guaranteed results with Citrus.
Check out what our customers have to say about us here.
And If you’d like to know more about how Citruslabs can help you recruit more effectively, get in touch with our team here.